This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pfizer, Flynn Pharma lodge fresh appeals of UK fines for ‘excessive’ drug pricing

By Simon Zekaria ( October 26, 2022, 15:32 GMT | Insight) -- Pfizer and Flynn Pharma today freshly appealed fines of tens of millions of pounds levied by the UK competition regulator for abusing dominant positions through overcharging for epilepsy drugs. More than four years ago, the watchdog's original landmark antitrust sanctions against the pharmaceutical companies were quashed in a specialized court.Pfizer and Flynn Pharma today freshly appealed fines levied by the UK competition regulator for abusing dominant positions through epilepsy-drug pricing, more than four years after courts quashed previous sanctions against the firms by the watchdog....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections